ReviewOncology and therapy2026
Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review.
Review in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A view from the periphery: trial design, commercial competition, and the access gap in multiple myeloma.The oncologist · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, the multiple myeloma (MM) landscape varies widely, with incidence, treatment patterns, outcomes, and healthcare resource utilization (HCRU) differing across countries and regions. Many factors contribute to these differences, including ethnicity, awareness, and socioeconomic influences. This is the first analysis aiming to explore factors associated with myeloma incidence and patient characteristics in the Middle East and North Africa (MENA) region. A literature search was conducted using PubMed and Embase from 1 January 2015 to 30 May 2025. Articles reporting outcomes of interest in patients with MM in the relevant MENA countries (Egypt, Saudi Arabia, Turkey, and the United Arab Emirates) were identified. Of 1400 articles identified in the search, 94 were included; four articles were added post hoc as gray literature. Most reported findings from retrospective observational studies (n = 66); more than half were conducted in Turkey. The age-standardized incidence rate in MENA was 1.49 per 100,000 people in 2019; median age at diagnosis was lower in the region (range 43-70 years) than that in global reports (70 years). Nearly half (49.7%) of all patients were treated with a regimen containing bortezomib; the second-most frequently used drug was lenalidomide in newly diagnosed MM and daratumumab in relapsed/refractory MM. Few patients (< 1%) were treated with quadruplet regimens. Overall response rates were generally high (35-90.2%), while survival outcomes varied (median progression-free and overall survival ranged from 2-97.7 months and 4-125.3 months, respectively). Adverse events were inconsistently reported across the studies; hematologic adverse events and peripheral neuropathy were commonly reported. HCRU data in the region were limited. We identified a paucity of comprehensive data on the epidemiology and management of MM in MENA. Improved understanding of treatment patterns and HCRU in the region may provide pathways to advancing access to newer therapies that can alleviate the disease and treatment burden of MM in MENA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.